Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer.

625 Background: The Oncotype DX Recurrence Score is a clinically validated molecular test that can be used to predict the risk of distant recurrence and the likelihood of chemotherapy benefit among patients with newly diagnosed ER+ early stage breast cancer. By avoiding unnecessary chemotherapy use in patients with low Recurrence Score disease, toxicity and cost could be reduced. By giving chemotherapy to patients with high Recurrence Score disease, recurrences could be reduced. The objective of this investigation was to determine if patient or practice characteristics drive utilization. Methods: Early stage breast cancer patients who were diagnosed between January 2008 and June 2009 with ER+, LN-, HER2 non-amplified tumors, who were evaluated within the USON, and who were registered within the EMR were included. Patients enrolled on clinical trial or treated for another cancer during the study period were excluded. The oncology specific electronic medical record (EMR) system software iKnowMed is used wit...